利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

47 条记录 (耗时 0.032 秒)

    Multiparticulate L-menthol formulations and related methods
    2.
    发明授权
    Multiparticulate L-menthol formulations and related methods 有权
    多片L-薄荷醇配方及相关方法

    公开(公告)号：US08568776B2

    公开(公告)日：2013-10-29

    申请号：US13367747

    申请日：2012-02-07

    申请人： Syed M. Shah ,  Daniel Hassan ,  Sarah Hassan

    发明人： Syed M. Shah ,  Daniel Hassan ,  Sarah Hassan

    IPC分类号： A61K9/26

    CPC分类号： A61K31/045 ,  A61K9/0053 ,  A61K9/50 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5073 ,  A61K9/5089

    摘要： Enteric coated multiparticulate formulations that use L-menthol as an active ingredient are disclosed. In one embodiment, the multiparticulate formulation comprises a plurality of particulates having a reduced release under gastric conditions and an elevated release at neutral pH. The particulates comprise a core comprising L-menthol as an active ingredient. The L-menthol is supplied to the core as an at least 80% pure L-menthol material. An enteric coating is over the core. The enteric coating is effective to release at least about 80% of the L-menthol within about two hours of being placed in a substantially neutral pH environment. Other aspects of the invention include methods of making and methods of using the multiparticulate formulations.

    摘要翻译： 公开了使用L-薄荷醇作为活性成分的肠溶包衣多颗粒制剂。 在一个实施方案中，多颗粒制剂包含多个在胃条件下具有减少的释放并且在中性pH下升高释放的颗粒。 颗粒包含包含L-薄荷醇作为活性成分的核心。 将L-薄荷醇作为至少80％纯的L-薄荷醇材料供应至核心。 肠衣是核心的。 肠溶衣在放置在基本上中性的pH环境中的约两小时内有效释放至少约80％的L-薄荷醇。 本发明的其它方面包括制备方法和使用多颗粒制剂的方法。

    MULTIPARTICULATE L-MENTHOL FORMULATIONS AND RELATED METHODS
    5.
    发明申请
    MULTIPARTICULATE L-MENTHOL FORMULATIONS AND RELATED METHODS 有权
    多重L-精液配方及相关方法

    公开(公告)号：US20120207842A1

    公开(公告)日：2012-08-16

    申请号：US13367747

    申请日：2012-02-07

    申请人： SYED M. SHAH ,  DANIEL HASSAN ,  SARAH HASSAN

    发明人： SYED M. SHAH ,  DANIEL HASSAN ,  SARAH HASSAN

    IPC分类号： A61K31/045 ,  B05D5/00 ,  B05D3/00 ,  A61K9/50 ,  A61P1/00

    CPC分类号： A61K31/045 ,  A61K9/0053 ,  A61K9/50 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5073 ,  A61K9/5089

    摘要： Enteric coated multiparticulate formulations that use L-menthol as an active ingredient are disclosed. In one embodiment, the multiparticulate formulation comprises a plurality of particulates having a reduced release under gastric conditions and an elevated release at neutral pH. The particulates comprise a core comprising L-menthol as an active ingredient. The L-menthol is supplied to the core as an at least 80% pure L-menthol material. An enteric coating is over the core. The enteric coating is effective to release at least about 80% of the L-menthol within about two hours of being placed in a substantially neutral pH environment. Other aspects of the invention include methods of making and methods of using the multiparticulate formulations.

    摘要翻译： 公开了使用L-薄荷醇作为活性成分的肠溶包衣多颗粒制剂。 在一个实施方案中，多颗粒制剂包含多个在胃条件下具有减少的释放并且在中性pH下升高释放的颗粒。 颗粒包含包含L-薄荷醇作为活性成分的核心。 将L-薄荷醇作为至少80％纯的L-薄荷醇材料供应至核心。 肠衣是核心的。 肠溶衣在放置在基本上中性的pH环境中的约两小时内有效释放至少约80％的L-薄荷醇。 本发明的其它方面包括制备方法和使用多颗粒制剂的方法。

    Serotonin and norepinephrine reuptake inhibitor and uses thereof
    6.
    发明授权
    Serotonin and norepinephrine reuptake inhibitor and uses thereof 失效
    5-羟色胺和去甲肾上腺素再摄取抑制剂及其应用

    公开(公告)号：US07595340B2

    公开(公告)日：2009-09-29

    申请号：US11486336

    申请日：2006-07-13

    申请人： Syed M. Shah ,  Mahdi B. Fawzi ,  Eric C. Ehrnsperger ,  Panolil Raveendranath

    发明人： Syed M. Shah ,  Mahdi B. Fawzi ,  Eric C. Ehrnsperger ,  Panolil Raveendranath

    IPC分类号： A61K31/35 ,  C07D309/10

    CPC分类号： C07D309/10 ,  A61K9/20 ,  A61K9/48

    摘要： Selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agoraphobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.

    摘要翻译： 提供选择性双重5-羟色胺和去甲肾上腺素再摄取抑制剂。 这些化合物具有较低的副作用特征，并且可用于治疗各种病症的组合物和产品，包括抑郁症，纤维肌痛，焦虑症，惊恐障碍，广场恐怖症，创伤后应激障碍，经前期焦虑障碍，注意力缺陷障碍， 强迫症，社会焦虑症，广泛性焦虑症，自闭症，精神分裂症，肥胖症，神经性厌食症，神经性贪食症，杜氏综合征，血管舒缩性潮红，可卡因和酒精成瘾，性功能障碍，边缘性人格障碍，纤维肌痛综合征，糖尿病性神经病变 疼痛，慢性疲劳综合征，疼痛，Shie Drager综合征，雷诺综合征，帕金森病和癫痫。